Skip to main content
. 2018 May 4;9(34):23704–23717. doi: 10.18632/oncotarget.25281

Figure 1.

Figure 1

Figure 1

Figure 1

Figure 1

Forest plots of pooled response rates in Carf treated RRMM patients: (A) Overall response rate of phase III studies, (B) Overall response rate of phase II and I/II studies, (C) Clinical benefit rate of phase III studies, (D) Clinical benefit rate of phase II and I/II studies.